Press Releases

First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of hemophilia A Ninth breakthrough therapy designation for Genentech’s portfolio of medicines Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),...

Additionally, Frank Vicini, MD, Chief Academic Officer for Michigan Healthcare Professionals and 21st Century Oncology and Professor of Radiation Oncology, discusses data from a landmark study recently presented at ASTRO 2015 and published in The Lancet that have...

Phase I data regarding the experimental cancer agent ONT-380 were presented recently at the 2015 San Antonio Breast Cancer Symposium, indicating initial efficacy in breast cancer patients with metastatic HER2+ breast cancer. The...

The importance of national screening Data published by Cancer Research UK and Public Health England’s National Cancer Intelligence Network have reported, for the first time & detected through different healthcare. The stages at which bowel...

European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all...

European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all...

The primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) with either advanced cirrhosis...